Atrial fibrillation in β-thalassemia Major Patients: Diagnosis, Management and Therapeutic Options.

Umberto BarberoFederico FornariSilvia GuarguagliCarmen Maria GagliotiFilomena LongoBaldassarre DoronzoMatteo AnselminoAntonio Piga

Published in: Hemoglobin (2018)

The prevalence of atrial fibrillation (AFib) in β-thalassemia major (β-TM) patients has increased in the last few years, reaching up to 33.0%. Several factors may drive this value to even more in the next few years. We summarized the main challenges in the management and therapy of AFib in this very specific group of patients.

Keyphrases

end stage renal disease
atrial fibrillation
ejection fraction
newly diagnosed
prognostic factors
patient reported outcomes
percutaneous coronary intervention
left ventricular
venous thromboembolism
direct oral anticoagulants
patient reported
oral anticoagulants
catheter ablation